+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ilumya 2019 U.S. Promotional Audit Report

  • ID: 5121331
  • Report
  • July 2020
  • 17 pages
  • MD Details
1 of 1
The 5 Key Questions Addressed by this Report:
  • How many physicians were reached by Ilumya through reportable promotional activity in 2019 and how does this compare to its peer set in the Psoriasis market?
  • What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend for each type of activity?
  • How does Sun Pharma's depth of coverage vary within key specialties (e.g., Dermatology) and how does this compare to its peers and the overall set of rep-accessible physicians?
  • How often are physicians receiving paid meals for Ilumya throughout the year (e.g., monthly, quarterly, annually)?
  • Who were the most frequent meal recipients and top paid speakers for Ilumya in 2019?
Data Sources and Methodology:
  • Author leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. More than five years of longitudinal data is available - covering payments to more than 1,000,000 U.S. healthcare professionals.
  • Over 8,500 paid interactions across 3,200 physicians made on behalf of Ilumya were carefully examined to support our analysis. In addition, interaction data from 21 peer products (i.e. Bryhali, Cosentyx, Duobrii, Enbrel, Enstilar, Humira, Impoyz, Inflectra, Olux, Otezla, Otrexup, Rasuvo, Remicade, Renflexis, Sernivo, Siliq, Skyrizi, Stelara, Taltz, Tremfya, and Ultravate) was leveraged to provide benchmarking and market insights.
Note: Product cover images may vary from those shown
2 of 1

Loading
LOADING...

Adroll
adroll